SG11201900394SA - Beta-lactamase inhibitors - Google Patents
Beta-lactamase inhibitorsInfo
- Publication number
- SG11201900394SA SG11201900394SA SG11201900394SA SG11201900394SA SG11201900394SA SG 11201900394S A SG11201900394S A SG 11201900394SA SG 11201900394S A SG11201900394S A SG 11201900394SA SG 11201900394S A SG11201900394S A SG 11201900394SA SG 11201900394S A SG11201900394S A SG 11201900394SA
- Authority
- SG
- Singapore
- Prior art keywords
- novartis
- international
- emeryville
- basel
- way
- Prior art date
Links
- 239000003781 beta lactamase inhibitor Substances 0.000 title abstract 3
- 229940126813 beta-lactamase inhibitor Drugs 0.000 title abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 4
- 241001227713 Chiron Species 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 241000894006 Bacteria Species 0.000 abstract 1
- 235000013382 Morus laevigata Nutrition 0.000 abstract 1
- 244000278455 Morus laevigata Species 0.000 abstract 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000002132 β-lactam antibiotic Substances 0.000 abstract 1
- 229940124586 β-lactam antibiotics Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Pyrrole Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property MD HIM 0 11101 010 11111 01 II 0 011101 100 11011101 OH I 11110 ill OEN Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2018/060926 Al 05 April 2018 (05.04.2018) WIP0 I PCT (51) International Patent Classification: SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, C07D 519/06 (2006.01) A61P 31/04 (2006.01) TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. A61K 31/535 (2006.01) CO7D 471/18 (2006.01) (84) Designated States (unless otherwise indicated, for every (21) International Application Number: kind of regional protection available): ARIPO (BW, GH, PCT/IB2017/055973 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (22) International Filing Date: UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 28 September 2017 (28.09.2017) TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (25) Filing Language: English MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (26) Publication Language: English TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (30) Priority Data: 62/401,022 28 September 2016 (28.09.2016) US Declarations under Rule 4.17: — (71) Applicant: NOVARTIS AG [CH/CH]; Lichtstrasse 35, as to applicant's entitlement to apply for and be granted a patent (Rule 4.1700) 4056 Basel (CH). Published: (72) Inventors: CASAREZ, Anthony; Novartis Institutes for — with international search report (Art. 21(3)) BioMedical Research, Inc., 5300 Chiron Way, Emeryville, _ before the expiration of the time limit for amending the 94608 (US). FUREGATI, Markus; Novartis Pharma AG, claims and to be republished in the event of receipt of Postfach, 4002 Basel (CH). KOCH, Guido; Novartis Phar- amendments (Rule 48.2(h)) ma AG, Postfach, 4002 Basel (CH). LIN, Xiaodong; No- vartis Institutes for BioMedical Research, Inc., 5300 Ch- iron Way, Emeryville, California 94608 (US). OSSOLA, Flavio; Novartis Pharma AG, Postfach, 4002 Basel (CH). RECK, Folkert; Novartis Institutes for BioMedical Re- search, Inc., 5300 Chiron Way, Emeryville, California 94608 (US). SIMMONS, Robert Lowell; Novartis Insti- tutes for BioMedical Research, Inc., 5300 Chiron Way, Emeryville, California 94608 (US). ZHU, Qingming; No- vartis Institutes for BioMedical Research, Inc., 5300 Chiron Way, Emeryville, California 94608 (US). (74) Agent: NOVARTIS AG; Lichtstrasse 35, 4056 Basel (CH). = (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, ,tD N 01 0 ,tDo 0 --.... hi Il 0 0 N 1-1 (54) Title: BETA-LACTAMASE INHIBITORS (57) : This invention pertains generally to compounds of Formula (A), as further described herein, which act as beta-lactamase inhibitors, and salts, crystalline forms and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds in combination with a beta-lactam antibiotic to treat infections caused by Gram-negative bacteria, including drug-resistant strains. \ os0 3 E1 (A) C
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662401022P | 2016-09-28 | 2016-09-28 | |
PCT/IB2017/055973 WO2018060926A1 (en) | 2016-09-28 | 2017-09-28 | Beta-lactamase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201900394SA true SG11201900394SA (en) | 2019-04-29 |
Family
ID=60191429
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201900394SA SG11201900394SA (en) | 2016-09-28 | 2017-09-28 | Beta-lactamase inhibitors |
Country Status (41)
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20190061A1 (en) | 2016-09-28 | 2019-03-26 | Novartis Ag | Beta-lactamase inhibitors |
US11897844B2 (en) | 2018-09-21 | 2024-02-13 | Api Corporation | Method for producing amino acid derivatives |
CN115368261A (en) * | 2022-07-29 | 2022-11-22 | 武汉理工大学 | Synthesis method of N-allyl-N-benzyl-2- (benzylamino) acetamide |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2116183B (en) | 1982-03-03 | 1985-06-05 | Genentech Inc | Human antithrombin iii dna sequences therefore expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby a process for expressing human antithrombin iii and pharmaceutical compositions comprising it |
CA2143519A1 (en) * | 1994-03-11 | 1995-09-12 | Markus Bohringer | Beta-lactams |
US6111090A (en) | 1996-08-16 | 2000-08-29 | Schering Corporation | Mammalian cell surface antigens; related reagents |
DK0920505T3 (en) | 1996-08-16 | 2008-09-08 | Schering Corp | Mammalian cell surface antigens and associated reagents |
EP1025228A4 (en) | 1997-10-21 | 2002-09-18 | Human Genome Sciences Inc | Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2 |
IL137409A0 (en) | 1998-02-09 | 2001-07-24 | Genentech Inc | Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same |
WO2001003720A2 (en) | 1999-07-12 | 2001-01-18 | Genentech, Inc. | Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs |
FR2812635B1 (en) | 2000-08-01 | 2002-10-11 | Aventis Pharma Sa | NOVEL HETEROCYCLIC COMPOUNDS, PREPARATION AND USE AS MEDICAMENTS IN PARTICULAR AS ANTI-BACTERIALS |
FR2825705B1 (en) | 2001-06-08 | 2005-05-20 | Aventis Pharma Sa | NOVEL HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-BACTERIANS |
FR2835186B1 (en) | 2002-01-28 | 2006-10-20 | Aventis Pharma Sa | NOVEL HETEROCYCLIC COMPOUNDS ACTIVE AS BETA-LACTAMASES INHIBITORS |
WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
US7439253B2 (en) | 2002-12-06 | 2008-10-21 | Novexel | Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors |
FR2848210B1 (en) | 2002-12-06 | 2007-10-19 | Aventis Pharma Sa | NOVEL HETEROCYCLIC COMPOUNDS, PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-BACTERIALS AND INHIBITORS OF BETA-LACTAMASES |
AU2003288675B2 (en) | 2002-12-23 | 2010-07-22 | Medimmune Limited | Antibodies against PD-1 and uses therefor |
AU2004244626A1 (en) | 2003-05-23 | 2004-12-09 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | GITR ligand and GITR ligand-related molecules and antibodies and uses thereof |
US20050048054A1 (en) | 2003-07-11 | 2005-03-03 | Shino Hanabuchi | Lymphocytes; methods |
WO2005055808A2 (en) | 2003-12-02 | 2005-06-23 | Genzyme Corporation | Compositions and methods to diagnose and treat lung cancer |
GB0409799D0 (en) | 2004-04-30 | 2004-06-09 | Isis Innovation | Method of generating improved immune response |
WO2006083289A2 (en) | 2004-06-04 | 2006-08-10 | Duke University | Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity |
EP2343320B1 (en) | 2005-03-25 | 2017-10-25 | GITR, Inc. | Anti-gitr antibodies and uses thereof |
CN109485727A (en) | 2005-05-09 | 2019-03-19 | 小野药品工业株式会社 | The human monoclonal antibodies of programmed death-1 (PD-1) and the method for carrying out treating cancer using anti-PD-1 antibody |
MX2007015942A (en) | 2005-07-01 | 2008-03-07 | Medarex Inc | Human monoclonal antibodies to programmed death ligand 1 (pd-l1). |
US20110212086A1 (en) | 2006-01-19 | 2011-09-01 | Genzyme Corporation | GITR Antibodies For The Treatment of Cancer |
WO2008039420A2 (en) | 2006-09-27 | 2008-04-03 | Merck & Co., Inc. | Novel inhibitors of beta-lactamase |
DK2170959T3 (en) | 2007-06-18 | 2014-01-13 | Merck Sharp & Dohme | ANTIBODIES AGAINST HUMAN PROGRAMMED DEATH RECEPTOR PD-1 |
ES2591281T3 (en) | 2007-07-12 | 2016-11-25 | Gitr, Inc. | Combination therapies that employ GITR binding molecules |
UA101966C2 (en) | 2008-01-18 | 2013-05-27 | Мерк Шарп Енд Доме Корп. | Beta-lactamase inhibitors |
ES2639857T3 (en) | 2008-02-11 | 2017-10-30 | Cure Tech Ltd. | Monoclonal antibodies for tumor treatment |
US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
JP2011526794A (en) | 2008-07-02 | 2011-10-20 | エマージェント プロダクト デベロップメント シアトル, エルエルシー | TGF-β antagonist multi-target binding molecule |
AR072999A1 (en) | 2008-08-11 | 2010-10-06 | Medarex Inc | HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE |
AU2009288289B2 (en) | 2008-08-25 | 2012-11-08 | Amplimmune, Inc. | PD-1 antagonists and methods of use thereof |
CA2734908A1 (en) | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Compositions of pd-1 antagonists and methods of use |
JPWO2010030002A1 (en) | 2008-09-12 | 2012-02-02 | 国立大学法人三重大学 | Foreign GITR ligand expressing cells |
FR2936951B1 (en) | 2008-10-10 | 2010-12-03 | Novexel | NOVEL COMBINATIONS OF ANTIBACTERIAL NITROGENIC HETEROCYCLIC COMPOUNDS WITH OTHER ANTIBACTERIAL COMPOUNDS AND THEIR USE AS MEDICAMENTS |
TWI686405B (en) | 2008-12-09 | 2020-03-01 | 建南德克公司 | Anti-pd-l1 antibodies and their use to enhance t-cell function |
EP3192811A1 (en) | 2009-02-09 | 2017-07-19 | Université d'Aix-Marseille | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
WO2010126820A2 (en) | 2009-04-30 | 2010-11-04 | Merck Sharp & Dohme Corp. | Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids |
KR101790802B1 (en) | 2009-09-03 | 2017-10-27 | 머크 샤프 앤드 돔 코포레이션 | Anti-gitr antibodies |
GB0919054D0 (en) | 2009-10-30 | 2009-12-16 | Isis Innovation | Treatment of obesity |
EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | Simultaneous inhibition of pd-l1/pd-l2 |
EP3112382A1 (en) | 2009-12-29 | 2017-01-04 | Emergent Product Development Seattle, LLC | Heterodimer binding proteins and uses thereof |
WO2013030735A1 (en) * | 2011-08-30 | 2013-03-07 | Wockhardt Limited | 1,6- diazabicyclo [3,2,1] octan- 7 - one derivatives and their use in the treatment of bacterial infections |
AU2012310136B2 (en) | 2011-09-13 | 2016-07-07 | Wockhardt Limited | Nitrogen containing compounds and their use |
US20130108641A1 (en) | 2011-09-14 | 2013-05-02 | Sanofi | Anti-gitr antibodies |
BR112014012819B1 (en) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | ANTI-PD-L1 ANTIBODY OR ANTIGEN BINDING FRAGMENT AND COMPOSITION |
US8796257B2 (en) | 2011-12-02 | 2014-08-05 | Naeja Pharmaceutical Inc. | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors |
US9025112B2 (en) | 2012-02-02 | 2015-05-05 | Apple Inc. | Display with color mixing prevention structures |
EP2814483A2 (en) | 2012-02-15 | 2014-12-24 | Rempex Pharmaceuticals, Inc. | Methods of treating bacterial infections |
KR20150003777A (en) | 2012-03-30 | 2015-01-09 | 큐비스트 파마슈티컬즈 인코포레이티드 | ISOXAZOLE β-LACTAMASE INHIBITORS |
TW201343645A (en) | 2012-03-30 | 2013-11-01 | Cubist Pharm Inc | 1,3,4-oxadiazole and 1,3,4-thiadiazole β-lactamase inhibitors |
AR090539A1 (en) | 2012-04-02 | 2014-11-19 | Astrazeneca Ab | INHIBITING COMPOUNDS OF B LACTAMASA |
UY34887A (en) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES |
CA2881169C (en) | 2012-08-25 | 2020-06-16 | Wockhardt Limited | 1,6-diazabicyclo [3,2,1]octan - 7 - one derivatives and their use in the treatment of bacterial infections |
WO2014141132A1 (en) | 2013-03-14 | 2014-09-18 | Naeja Pharmaceutical Inc. | NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS |
WO2015052682A1 (en) * | 2013-10-11 | 2015-04-16 | Wockhardt Limited | Nitrogen containing compounds and their use |
WO2016116788A1 (en) * | 2015-01-24 | 2016-07-28 | Wockhardt Limited | Nitrogen containing bicyclic compounds and their use in treatment of bacterial infections |
EP3075381A1 (en) * | 2015-04-03 | 2016-10-05 | Mutabilis | Heterocyclic compounds and their use in preventing or treating bacterial infections |
JP2018510198A (en) * | 2015-04-03 | 2018-04-12 | ミュタビリスMutabilis | Heterocyclic compounds and their use for the prevention or treatment of bacterial infections |
JOP20190061A1 (en) | 2016-09-28 | 2019-03-26 | Novartis Ag | Beta-lactamase inhibitors |
-
2017
- 2017-06-16 JO JOP/2019/0061A patent/JOP20190061A1/en unknown
- 2017-09-27 TW TW106133157A patent/TWI746652B/en active
- 2017-09-28 MY MYPI2019000304A patent/MY189632A/en unknown
- 2017-09-28 PL PL17791737T patent/PL3519419T3/en unknown
- 2017-09-28 HU HUE17791737A patent/HUE049788T2/en unknown
- 2017-09-28 US US16/323,668 patent/US10597396B2/en active Active
- 2017-09-28 MX MX2019003640A patent/MX2019003640A/en unknown
- 2017-09-28 MD MDE20190874T patent/MD3519419T2/en not_active IP Right Cessation
- 2017-09-28 AU AU2017335405A patent/AU2017335405B2/en not_active Ceased
- 2017-09-28 RS RS20200740A patent/RS60483B1/en unknown
- 2017-09-28 JP JP2019516249A patent/JP7094275B2/en active Active
- 2017-09-28 EA EA201990819A patent/EA036675B1/en not_active IP Right Cessation
- 2017-09-28 SG SG11201900394SA patent/SG11201900394SA/en unknown
- 2017-09-28 MA MA46356A patent/MA46356B1/en unknown
- 2017-09-28 CR CR20190104A patent/CR20190104A/en unknown
- 2017-09-28 ME MEP-2020-111A patent/ME03735B/en unknown
- 2017-09-28 CN CN201780060128.9A patent/CN109843894B/en active Active
- 2017-09-28 EP EP17791737.4A patent/EP3519419B1/en active Active
- 2017-09-28 BR BR112019002195-7A patent/BR112019002195A2/en not_active Application Discontinuation
- 2017-09-28 AR ARP170102682A patent/AR109737A1/en unknown
- 2017-09-28 ES ES20165564T patent/ES2902579T3/en active Active
- 2017-09-28 MA MA050427A patent/MA50427A/en unknown
- 2017-09-28 CA CA3030373A patent/CA3030373A1/en active Pending
- 2017-09-28 SI SI201730285T patent/SI3519419T1/en unknown
- 2017-09-28 WO PCT/IB2017/055973 patent/WO2018060926A1/en unknown
- 2017-09-28 PT PT177917374T patent/PT3519419T/en unknown
- 2017-09-28 UY UY0001037424A patent/UY37424A/en unknown
- 2017-09-28 LT LTEP17791737.4T patent/LT3519419T/en unknown
- 2017-09-28 PE PE2019000446A patent/PE20190459A1/en unknown
- 2017-09-28 DK DK17791737.4T patent/DK3519419T3/en active
- 2017-09-28 US US15/718,571 patent/US10065957B2/en active Active
- 2017-09-28 EP EP20165564.4A patent/EP3698796B1/en active Active
- 2017-09-28 CU CU2019000016A patent/CU24562B1/en unknown
- 2017-09-28 ES ES17791737T patent/ES2801874T3/en active Active
- 2017-09-28 UA UAA201900256A patent/UA123833C2/en unknown
- 2017-09-28 TN TNP/2019/000020A patent/TN2019000020A1/en unknown
- 2017-09-28 KR KR1020197008487A patent/KR20190058492A/en active IP Right Grant
-
2019
- 2019-01-09 ZA ZA2019/00137A patent/ZA201900137B/en unknown
- 2019-01-29 CL CL2019000232A patent/CL2019000232A1/en unknown
- 2019-02-15 PH PH12019500331A patent/PH12019500331A1/en unknown
- 2019-02-28 CO CONC2019/0001995A patent/CO2019001995A2/en unknown
- 2019-03-08 EC ECSENADI201916602A patent/ECSP19016602A/en unknown
- 2019-03-26 IL IL265626A patent/IL265626B/en unknown
-
2020
- 2020-06-17 CY CY20201100557T patent/CY1123062T1/en unknown
- 2020-06-19 HR HRP20200986TT patent/HRP20200986T1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
SG11201900163PA (en) | Macrocycle kinase inhibitors | |
SG11201811491YA (en) | Quinazoline and indole compounds to treat medical disorders | |
SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
SG11201407919WA (en) | Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ror[gamma] | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
SG11201810371XA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
SG11201811416VA (en) | Crystalline solid forms of a bet inhibitor | |
SG11201407575PA (en) | 5-amino[1,4]thiazines as bace 1 inhibitors | |
SG11201811712QA (en) | 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases | |
SG11201407591PA (en) | Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof | |
SG11201407184PA (en) | Process for preparation of optically pure and optionally substituted 2- (1 -hydroxy- alkyl) - chromen - 4 - one derivatives and their use in preparing pharmaceuticals | |
SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
SG11201811804QA (en) | Oxadiazolopyridine derivates for use as ghrelin o-acyl transferase (goat) inhibitors | |
SG11201809537VA (en) | Urea motif containing compounds and derivatives thereof as antibacterial drugs | |
SG11201900394SA (en) | Beta-lactamase inhibitors | |
SG11201908487YA (en) | Mitoriboscins: mitochondrial-based therapeutics targeting cancer cells, bacteria, and pathogenic yeast | |
SG11201804885TA (en) | Monomaleimide-functionalized platinum compounds for cancer therapy | |
SG11201902529WA (en) | Naphthyridinone derivatives and their use in the treatment of arrhythmia | |
SG11201908159QA (en) | Dual magl and faah inhibitors | |
SG11201407796YA (en) | Chromane compounds | |
SG11201903113TA (en) | Compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders |